BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14565167)

  • 1. Inflammation 2003-Sixth World Congress. Focus on chronic obstructive pulmonary disease. 2-6 August 2003, Vancouver, Canada.
    Rossi AG
    IDrugs; 2003 Sep; 6(9):838-40. PubMed ID: 14565167
    [No Abstract]   [Full Text] [Related]  

  • 2. Inflammation 2003-Sixth World Congress. 2-6 August 2003, Vancouver, Canada.
    Evans R
    IDrugs; 2003 Sep; 6(9):831-3. PubMed ID: 14565165
    [No Abstract]   [Full Text] [Related]  

  • 3. Inflammation 2003-Sixth World Congress. Anti-inflammatory mechanisms. 2-6 August 2003, Vancouver, Canada.
    Braddock M
    IDrugs; 2003 Sep; 6(9):841-4. PubMed ID: 14565168
    [No Abstract]   [Full Text] [Related]  

  • 4. Inflammation 2003-Sixth World Congress. Nitric oxide and IBD. 2-6 August 2003, Vancouver, Canada.
    Evans R
    IDrugs; 2003 Sep; 6(9):834-7. PubMed ID: 14565166
    [No Abstract]   [Full Text] [Related]  

  • 5. The COPD pipeline.
    Gross NJ
    COPD; 2010 Apr; 7(2):154-6. PubMed ID: 20397816
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of COPD: no longer nihilism, but there is still an urgent need for new therapies.
    Matera MG; Cazzola M
    Curr Opin Pharmacol; 2012 Jun; 12(3):225-8. PubMed ID: 22497842
    [No Abstract]   [Full Text] [Related]  

  • 7. Future of chronic obstructive pulmonary disease management.
    D'Urzo A; Vogelmeier C
    Expert Rev Respir Med; 2012 Jun; 6(3):285-99. PubMed ID: 22788943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug treatment for chronic obstructive pulmonary disease.
    Wark P
    IDrugs; 2003 Sep; 6(9):874-9. PubMed ID: 12964067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The COPD Pipeline.
    Gross NJ
    COPD; 2009 Dec; 6(6):488-9. PubMed ID: 19938973
    [No Abstract]   [Full Text] [Related]  

  • 10. Inflammation 2005 - Seventh World Congress. Respiratory inflammation.
    Parnham MJ
    IDrugs; 2005 Oct; 8(10):783-6. PubMed ID: 16254789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for chronic obstructive pulmonary disease.
    Matera MG; Calzetta L; Segreti A; Cazzola M
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):61-82. PubMed ID: 22335427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian Thoracic Society Guidelines for Pharmacotherapy for Stable Chronic Obstructive Pulmonary Disease.
    Ebell MH
    Am Fam Physician; 2024 Jun; 109(6):581-582. PubMed ID: 38905564
    [No Abstract]   [Full Text] [Related]  

  • 13. NICE guidelines for chronic obstructive pulmonary disease: implications for primary care.
    Gruffydd-Jones K; Jones MM
    Br J Gen Pract; 2011 Feb; 61(583):91-2. PubMed ID: 21276335
    [No Abstract]   [Full Text] [Related]  

  • 14. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?
    Salama RO; Young PM; Rogueda P; Lallement A; Iliev I; Traini D
    Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of the GOLD documents for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Controversies and questions.
    Yusen RD
    Am J Respir Crit Care Med; 2013 Jul; 188(1):4-5. PubMed ID: 23815714
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic Obstructive Pulmonary Disease--SMi's Second Annual Conference. 10-11 March 2004, London, UK.
    De La Rue SA
    IDrugs; 2004 Apr; 7(4):318-22. PubMed ID: 15057634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
    Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
    BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Rationale for GesEPOC in Our Environment.
    Arnedillo Muñoz A
    Arch Bronconeumol; 2017 Jun; 53(6):293-294. PubMed ID: 28495074
    [No Abstract]   [Full Text] [Related]  

  • 19. Basic and clinical research into chronic obstructive pulmonary.
    Li YY; Liu XS; Xu YJ
    Chin Med J (Engl); 2010 Feb; 123(4):491-7. PubMed ID: 20193492
    [No Abstract]   [Full Text] [Related]  

  • 20. Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? YES.
    Salpeter SR
    Can Fam Physician; 2007 Aug; 53(8):1290-7. PubMed ID: 17872838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.